PRISM BioLab Co.,LTD (TYO:206A)

Japan flag Japan · Delayed Price · Currency is JPY
192.00
+11.00 (6.08%)
At close: Mar 27, 2026
Market Cap7.09B -29.1%
Revenue (ttm)684.61M +83.8%
Net Income-927.75M
EPS-25.26
Shares Out36.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume336,100
Average Volume1,064,585
Open180.00
Previous Close181.00
Day's Range180.00 - 193.00
52-Week Range132.00 - 292.00
Betan/a
RSI49.93
Earnings DateMay 14, 2026

About PRISM BioLab Co.,LTD

PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform. The company was founded in 2006 and is based in Fujis... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 35
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 206A
Full Company Profile

Financial Performance

In fiscal year 2025, PRISM BioLab Co.,LTD's revenue was 677.33 million, an increase of 121.62% compared to the previous year's 305.62 million. Losses were -833.70 million, -20.56% less than in 2024.

Financial Statements